D3 Bio names new independent board member
15 March 2024 -

D3 Bio, an emerging global biotechnology company, announced on Thursday that it has named Antoine Yver, MD, MSc as an independent board member.

Dr Yver has served in the global pharmaceutical industry for 34 years, with a focus on cancer drug discovery and development. He earlier served as executive vice-president and global head, R&D Oncology at Daiichi Sankyo and senior vice-president, GMed Head Oncology and GMD China lead at AstraZeneca. Presently, he serves as chaiman of Development at Centessa Pharmaceuticals and as independent director on the board of Sanofi SA.

Yver is also the Founder of 'The Blue Bears Special Meals'.

Dr George Chen, Chairman and CEO at D3 Bio, said 'I had the privilege of working with Dr Yver at Astra Zeneca, and today I am honored to extend a warm welcome to Dr Yver, our new independent board member. Dr Yver has been a special advisor to D3 Bio since March 2023, provided strategic and scientific advice, and made significant contributions to D3 Bio. In his new role, I am confident Dr Yver, with his proven track record, expertise in drug development and deal making, and his substantial direct global leadership experience, will play a pivotal role in steering D3 Bio towards growing into an established global biotech company.'